Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc - Full Text View

Purpose

Hypothesis: Intensification of current ARV regimens with maraviroc will result in more complete suppression of viral replication, particularly in the gastrointestinal mucosa with resultant reduction in markers of immune activation and improved GI immune reconstitution.

Condition	Intervention	Phase
HIV Infections	Drug: Maraviroc	Phase 1

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment
Official Title:	A Two-Arm, Single Site, Proof of Concept Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc, a CCR5 Antagonist (ADARC 2007-02)

Resource links provided by NLM:

Genetics Home Reference related topics: complement factor I deficiency

MedlinePlus related topics: HIV/AIDS

Drug Information available for: Abacavir Maraviroc

U.S. FDA Resources

Further study details as provided by Rockefeller University:

Primary Outcome Measures:

MMC HIV RNA [ Time Frame: 24 weeks ] [ Designated as safety issue: No ]

Enrollment:	8
Study Start Date:	September 2007
Study Completion Date:	May 2011
Primary Completion Date:	May 2011 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
Experimental: 1 ARM A: Intensification with maraviroc for 24 weeks at one of the following doses: 150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor 600 mg orally BID when coadministered with efavirenz or nevirapine	Drug: Maraviroc ARM A: Addition of maraviroc to baseline ARV medications for 24 weeks at one of the following doses: 150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor 600 mg orally BID when coadministered with efavirenz or nevirapine ARM B: Addition of an additional NRTI to baseline ARV medications for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above: Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc. Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc. Addition of tenofovir 300 mg daily to an abacavir containing regimen for 12 weeks then replacing the tenofovir with maraviroc.
Active Comparator: 2 ARM B Intensification with an additional NRTI for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above: Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofovir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.	Drug: Maraviroc ARM A: Addition of maraviroc to baseline ARV medications for 24 weeks at one of the following doses: 150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor 600 mg orally BID when coadministered with efavirenz or nevirapine ARM B: Addition of an additional NRTI to baseline ARV medications for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above: Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc. Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc. Addition of tenofovir 300 mg daily to an abacavir containing regimen for 12 weeks then replacing the tenofovir with maraviroc.

Arms

Assigned Interventions

Experimental: 1

ARM A:

Intensification with maraviroc for 24 weeks at one of the following doses:

150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor
600 mg orally BID when coadministered with efavirenz or nevirapine

Drug: Maraviroc

ARM A:

Addition of maraviroc to baseline ARV medications for 24 weeks at one of the following doses:

150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor
600 mg orally BID when coadministered with efavirenz or nevirapine

ARM B:

Addition of an additional NRTI to baseline ARV medications for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:

Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc.
Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.
Addition of tenofovir 300 mg daily to an abacavir containing regimen for 12 weeks then replacing the tenofovir with maraviroc.

Active Comparator: 2

ARM B

Intensification with an additional NRTI for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:

Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc
Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofovir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.

Drug: Maraviroc

ARM A:

Addition of maraviroc to baseline ARV medications for 24 weeks at one of the following doses:

150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor
600 mg orally BID when coadministered with efavirenz or nevirapine

ARM B:

Addition of an additional NRTI to baseline ARV medications for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:

Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc.
Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.
Addition of tenofovir 300 mg daily to an abacavir containing regimen for 12 weeks then replacing the tenofovir with maraviroc.

Detailed Description:

DURATION: Subjects will participate for a minimum of 28 weeks.
SAMPLE SIZE: 18 subjects randomized 2:1 continued ARVs plus maraviroc versus continued ARVs plus additional ARV to be determined based on baseline ARV regimen.
REGIMEN: At entry, subjects will be randomized to one of the following in a 2:1 ratio:

ARM A:

Intensification with maraviroc for 24 weeks at one of the following doses:

150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor
600 mg orally BID when coadministered with efavirenz or nevirapine

ARM B

Intensification with an additional NRTI for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:

Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc
Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofovir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.

The objectives of this study are:

To determine whether intensification of current ARV regimens with maraviroc will result in more complete suppression of viral replication and improved immune reconstitution in GI mucosal lymphoid compartment based on:

Reduction in normalized levels of CD4+MMC HIV-1 RNA as determined by PCR pre- and post- intensification at week 12 in Arm A versus Arm B.
Reduction in normalized levels of CD4+ mucosal mononuclear cell (MMC) HIV-1 RNA at week 12 compared to baseline in Arm A.
Reduction in %CD4+MMC HIV-1 RNA positive as determined by PCR pre- and post- intensification between Arm A and Arm B as well as week 12 and 24 post maraviroc intensification.
Levels of CD4+ T cells in GALT (% by flow and absolute #s by immunohistochemistry).
Phenotype of cells in GALT by flow (memory, naive, R5, X4, dual expressing).
Levels of activation of CD4 and CD8 in PB and GALT using HLA DR and CD 38.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Documented treatment with combination antiviral therapy (ARV) during acute and early HIV-1 infection defined as:
- Negative ELISA/Western Blot or indeterminate Western Blot in the presence of HIV-1 RNA>5,000 copies/ml
- Positive HIV-1 serology with a detuned ELISA O.D. value below 1.0
- A documented negative serology within 180 days of screening and a positive HIV-1 serology at screening
Treatment for at least one year with ARVs
Plasma HIV-1 RNA levels below detection for at least 6 months
CCR5 tropic virus pretreatment using the Monogram assay
GI biopsy at study entry
Agree to subsequent GI biopsy at 12 and 24 weeks
Laboratory values obtained within 45 days prior to study entry.
- Absolute neutrophil count (ANC) ≥500/mm³
- Hemoglobin ≥9.0 g/dL
- Platelet count ≥80,000/mm³
- AST (SGOT), ALT (SGPT), and alkaline phosphatase < 5.0 x ULN
- Total bilirubin ≤ 2.5 X ULN if not on atazanavir containing regimen
- PT/PTT within 1.5 control
- Calculated creatinine clearance ≥60 mL/min as estimated by the Cockcroft Gault equation:
- For men, (140 - age in years) x (body weight in kg) / (serum creatinine in mg/dL x 72) = CrCl (mL/min)
- For women, multiply the result by 0.85 = CrCl (mL/min) NOTE: A program to assist in calculations is available on the DMC web site at: http://www.fstrf.org/ACTG/ccc.html
For women of reproductive potential, negative serum or urine pregnancy test within 48 hours prior to initiating study medications unless otherwise specified by product labeling.
Female candidates of reproductive potential is defined as girls who have reached menarche or women who have not been post-menopausal for at least 24 consecutive months (i.e., who have had menses within the preceding 24 months) or have not undergone surgical sterilization (e.g., hysterectomy, or bilateral oophorectomy, or bilateral tubal ligation).
Contraception requirements:
- Female candidates of reproductive potential, who are participating in sexual activity that could lead to pregnancy, must agree that they will use at least one reliable method of contraception while receiving the protocol-specified drugs and for 6 weeks after stopping the medications.
- Male Candidates: If you are a heterosexual male, you and your sexual partner must agree to use acceptable methods of birth control during the entire study. Acceptable methods of birth control include intrauterine device (IUD), diaphragm with spermicide,condoms or not having sex. Oral contraceptives alone are not an acceptable method of birth control.
Men and women age ≥18 years.
Participants must be HLA-B5701 negative if not taking abacavir as part of their regimen.
Ability and willingness of subject to give written informed consent.

Exclusion Criteria:

Currently breast-feeding.
Use of immunomodulators (e.g., interleukins, interferons, cyclosporine), HIV vaccine, systemic cytotoxic chemotherapy, or investigational therapy within 30 days prior to study entry. NOTE: Subjects receiving stable physiologic glucocorticoid doses, defined as prednisone ≤ 10 mg/day, will not be excluded.
Known allergy/sensitivity to study drugs or their formulations.
Active drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements.
Serious illness requiring systemic treatment and/or hospitalization until candidate either completes therapy or is clinically stable on therapy, in the opinion of the site investigator, for at least 7 days prior to study entry.
Pretreatment viral population that is either dual mixed tropic or X4 tropic using the Monogram assay
Current imprisonment or involuntary incarceration in a medical facility for psychiatric or physical (e.g., infectious disease) illness.
Any other clinical conditions or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the requirements.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00703586

Locations

United States, New York
Rockefeller University Hospital
New York, New York, United States, 10065

Sponsors and Collaborators

Rockefeller University

Aaron Diamond AIDS Research Center

Pfizer

Investigators

Principal Investigator:

Martin Markowitz, MD

Rockefeller University

More Information

No publications provided

Responsible Party:	Rockefeller University
ClinicalTrials.gov Identifier:	NCT00703586 History of Changes
Other Study ID Numbers:	MMA-0612
Study First Received:	June 19, 2008
Last Updated:	October 22, 2012
Health Authority:	United States: Institutional Review Board

Keywords provided by Rockefeller University:

Maraviroc
Treatment Experienced

Additional relevant MeSH terms:

HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes

Immune System Diseases
Slow Virus Diseases
Antiviral Agents
Protease Inhibitors
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 13, 2013